ライフサイエンスコーパス: Crohn

1 Crohn's disease (CD) has been associated with an increas

2 Crohn's disease (CD) is a chronic gastrointestinal disea

3 Crohn's disease (CD) is a chronic relapsing inflammatory

4 Crohn's disease (CD) is characterized by an imbalance of

5 Crohn's disease (CD) patients suffer postprandial aversi

6 Crohn's disease and ulcerative colitis are chronic and p

7 Crohn's disease and ulcerative colitis are complex disea

8 Crohn's disease and ulcerative colitis are driven by bot

9 Crohn's disease and ulcerative colitis are the two forms

10 Crohn's disease causes chronic inflammation in the gastr

11 Crohn's disease is a complex disease, and treatment shou

12 Crohn's disease is a relapsing and remitting inflammator

13 Crohn's disease is an inflammatory bowel disease that is

14 Crohn's patients report significantly more disturbed sle

15 truncation in colon biopsy specimens from 16 Crohn's disease (CD) and 6 ulcerative colitis (UC) patie

16 The present work recruited 20 Crohn's disease patients in remission (CDs) and 20 age-g

17 = 147), rheumatoid arthritis (RA, n = 229), Crohn's disease (n = 148), or ulcerative colitis (n = 36

18 sease (rg = 0.12 +/- 0.03, P = 2.49 x 10-4), Crohn's disease (rg = 0.097 +/- 0.06, P = 3.27 x 10-3),

19 patients with ulcerative colitis (n = 4671), Crohn's disease (n = 3780), and IBD unclassified (n = 99

20 inflamed and non-inflamed colonic mucosa [50 Crohn's disease (CD); 80 ulcerative colitis (UC); 31 con

21 A total of 193 patients (57% female and 64% Crohn's disease) were included, with a median daily TG d

22 with ulcerative colitis 4.0, 95% CI 3.4-4.7; Crohn's disease 2.3, 95% CI 1.8-3.0; and IBD unclassifie

23 SAMP mice, mice that spontaneously develop a Crohn's-like ileitis.

24 c bacteria, including Ruminococcus gnavus, a Crohn's disease-associated pathobiont.

25 ts from pyroptosis and gut inflammation in a Crohn's disease experimental mouse model.

26 be a new option for the treatment of active Crohn's disease.

27 e treatment of moderately to severely active Crohn's disease (CD).

28 rity study, we enrolled patients with active Crohn's disease who had not responded to, or were intole

29 CT-P13 to infliximab in patients with active Crohn's disease.

30 Neutrophils from patients with acute Crohn's disease, rheumatoid arthritis, or sepsis were su

31 iated with time to surgical recurrence after Crohn ileocolectomy.

32 nduction of TNFalpha, ultimately aggravating Crohn's disease in the AGLCD patient, which can be rever

33 Although Crohn's disease (CD) and ulcerative colitis (UC) have be

34 d in cognitive and affective functions among Crohn's disease (CD) patients.

35 d to examine possible symptom profiles among Crohn's disease (CD) and ulcerative colitis (UC) patient

36 E mediated gastrointestinal food allergy and Crohn's disease, we tested whether therapeutic feeds eff

37 ne diseases such as rheumatoid arthritis and Crohn's disease.

38 ated the common genetic basis between CC and Crohn's disease (CD), ulcerative colitis (UC), and celia

39 nia, low-density-lipoprotein cholesterol and Crohn's disease.

40 e colitis (UC) with concurrent colectomy and Crohn disease (CD) with concurrent small bowel resection

41 nsists of 2 subtypes: ulcerative colitis and Crohn disease.

42 D), which consists of ulcerative colitis and Crohn's disease, are a significant medical burden-70 000

43 (IBD), that includes ulcerative colitis and Crohn's disease, can affect not only the gastrointestina

44 agement scenarios for ulcerative colitis and Crohn's disease.

45 wel disease including ulcerative colitis and Crohn's disease.

46 ease continuum within ulcerative colitis and Crohn's disease.

47 ory diseases, such as ulcerative colitis and Crohn's disease.

48 to cardiovascular and metabolic diseases and Crohn's disease.

49 lonality in systemic lupus erythematosus and Crohn's disease that was dominated by the IgA isotype, t

50 e of CD, analyzing results from the Food and Crohn's Disease Exacerbation Study (FACES) trial.

51 ient was compared to healthy individuals and Crohn's disease patients regarding immune cell compositi

52 l markers in ilea of healthy individuals and Crohn's disease patients.

53 m are involved in three viral infections and Crohn's disease.

54 on of acquired generalized lipodystrophy and Crohn's disease (AGLCD) featuring a lack of adipose tiss

55 this modification might contribute to PD and Crohn's disease.

56 the intestinal mucosa in healthy people and Crohn's disease patients and identified fungi specifical

57 ute pouchitis (n = 6), chronic pouchitis and Crohn's-like disease of the pouch (n = 27), normal pouch

58 s1734907 modulates risk of schizophrenia and Crohn's disease via altered methylation and expression o

59 associated with systemic sclerosis (SSc) and Crohn's disease (CD), some of which confer susceptibilit

60 disease, hereditary polyposis syndromes and Crohn's disease.

61 hepatitis C, psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis and who were in c

62 phagy in human inflammatory diseases such as Crohn disease was first identified by genome-wide associ

63 Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are characterized

64 PD) and also to autoimmune disorders such as Crohn's disease.

65 everity of gut-associated conditions such as Crohn's Disease.

66 ergent genes and pathways in 177 small bowel Crohn disease patients and controls.

67 to address severe and extensive small bowel Crohn's disease presenting with 3 severely fibrotic and

68 ivity and predicting outcomes in small bowel Crohn's disease.

69 s largely through CARD9 and is recognized by Crohn's disease patient anti-fungal antibodies.

70 the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained a

71 sceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic p

72 diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic p

73 has been associated with ulcerative colitis, Crohn's disease and potentially could have links with co

74 ceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac dise

75 for children with undifferentiated colitis, Crohn's disease, and ulcerative colitis.

76 in patients with anti-TNF-resistant colonic Crohn's disease (cCD) and ulcerative colitis (UC).

77 active inflammation in patients with colonic Crohn's Disease.

78 rus as well as in the inflammatory condition Crohn's disease.

79 Guts UK, Crohn's and Colitis UK, Cure Crohn's Colitis, AbbVie, Merck Sharp and Dohme, Napp Pha

80 kout and myeloid knockout (MKO) mice develop Crohn's-like intestinal inflammation when fed cholate-co

81 n why patients with XLA are prone to develop Crohn's disease.

82 ), and TNF(DeltaARE)(/+) mice, which develop Crohn's-like ileitis.

83 ammatory potential on the risk of developing Crohn's disease (CD) and ulcerative colitis (UC).

84 arnelian's effectiveness on type 2 diabetes, Crohn's disease, Parkinson's disease, and industrialized

85 ts were grouped based on ultimate diagnosis: Crohn's disease (CD), Irritable bowel syndrome (IBS), NS

86 We assessed the ability of the different Crohn's disease monitoring methods used to predict the o

87 of developing the inflammatory bowel disease Crohn's disease, thus suggesting that the loss of the im

88 ed twelve patients (72%) had active disease (Crohn's Disease Activity Index > 150) and 44 patients (2

89 ts (28%) were in clinical remission disease (Crohn's Disease Activity Index < 150).

90 uding asthma, breast cancer, celiac disease, Crohn's disease, Parkinson's disease and type 2 diabetes

91 h the susceptibility to Parkinson's disease, Crohn's disease, and mycobacteria infection.

92 pathogenesis of inflammatory bowel diseases-Crohn disease and ulcerative colitis-caused by untoward

93 extensive microbial product influx, driving Crohn-like enteritis.

94 re in patients with extensive fibrostenosing Crohn disease of the small bowel.

95 ns in patients with extensive fibrostenosing Crohn's jejuno-ileitis.

96 ed mucosa and associated with fibrostenosing Crohn's disease.

97 erative time has been recently developed for Crohn's disease (CD) patients.

98 rs following ileocolonic resection (ICR) for Crohn disease (CD) in a nationwide cohort study SUMMARY

99 Two sisters, initially managed for Crohn's disease based upon clinical, imaging and patholo

100 etic resonance index of activity (MARIA) for Crohn's disease (CD) is used to assess the activity of l

101 dy-mass index (BMI), and height, but not for Crohn disease or ulcerative colitis.

102 The most common surgery performed for Crohn disease is ileocolectomy.

103 ommon genetic variant increases the risk for Crohn's disease and leprosy.

104 s the only established dietary treatment for Crohn's disease (CD), but its acceptability is limited.

105 tribute to the development of or result from Crohn's disease.

106 axis to be potentially exploitable in future Crohn disease interventions.

107 mean age was 15.1 (SD 1.7) years, 69.9% had Crohn's disease, and 30.1% had ulcerative colitis or IBD

108 Half of the patients had Crohn's disease, and half had ulcerative colitis.

109 0 [50%] women; 602 [56%] diagnosed as having Crohn disease), 919 (311 affected and 608 unaffected) we

110 ng its immune-stimulatory potential in human Crohn's disease remains sparse.

111 ining environmental factors and risk of IBD (Crohn's disease [CD] or ulcerative colitis [UC]).

112 Nineteen cases were identified: Crohn's disease (n = 8; 42%) and juvenile idiopathic art

113 Nineteen cases were identified; Crohn's disease (n=8;42%) and juvenile idiopathic arthri

114 nical benefits of cytokine blockade in ileal Crohn's disease (iCD) are limited to a subset of patient

115 In Crohn's disease, the characteristic expansion of mesente

116 In Crohn's disease, the DII was positively associated with

117 Flagellin is an immunodominant Ag in Crohn disease, with many patients showing anti-flagellin

118 clonality of flagellin-reactive CD4 cells in Crohn patients, we used a common CD154-based enrichment

119 ng strategy for predicting disease course in Crohn's disease remains undefined.

120 rs influencing intestinal ACE2 expression in Crohn's disease (CD), ulcerative colitis (UC), and non-i

121 activation of fetal transcription factors in Crohn's disease.

122 had little impact on intestinal fibrosis in Crohn's disease (CD), increased understanding of the pat

123 small intestinal epithelial cells (IECs) in Crohn's disease (CD) exhibit impaired GPX4 activity and

124 restore CD39 along with immunohomeostasis in Crohn's disease.

125 arker for active ileocolonic inflammation in Crohn's disease (CD) and assess its diagnostic performan

126 ing chronic gastrointestinal inflammation in Crohn's disease (CD) and ulcerative colitis (UC), in hum

127 Intestinal inflammation in Crohn's disease (CD) is caused by mucosal immune system

128 edictions from genes known to be involved in Crohn's disease, to genes that are not known to have an

129 ents with a decrease of 70 points or more in Crohn's Disease Activity Index (CDAI) from baseline to w

130 IS) and its effects on bowel preservation in Crohn disease (CD).

131 ctive control of the inflammatory process in Crohn's disease (CD) is reflected in intestinal mucosal

132 rrence score and surgical recurrence rate in Crohn disease (CD).

133 umans, gut microbiota density was reduced in Crohn's disease, ulcerative colitis, and ileal pouch-ana

134 actor with an established regulatory role in Crohn's disease pathogenesis.

135 e reminiscent of fibrotic strictures seen in Crohn disease patients.

136 matory diet with statistical significance in Crohn's disease.

137 The personalised anti-TNF therapy in Crohn's disease study (PANTS) is a prospective observati

138 Unlike in Crohn's disease, no significant differences were found i

139 ab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originato

140 atients with ulcerative colitis and inactive Crohn's disease have lower levels of CRT, which might co

141 mmatory bowel diseases (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are mu

142 Inflammatory bowel diseases, which include Crohn's disease and ulcerative colitis, affect several m

143 Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis.

144 ed with inflammatory bowel disease including Crohn's disease and ulcerative colitis, the arthritis re

145 th numerous immunological diseases including Crohn's disease, multiple sclerosis, chronic lymphocytic

146 ependently implicated in diseases, including Crohn disease and systemic lupus erythematosus.

147 n diseases and systemic disorders, including Crohn's disease and pancreatic cancer.

148 Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a d

149 inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, and in 2,4,6-tri

150 nflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are associated w

151 were correlated with the following indexes: Crohn's disease activity index (CDAI), fCal, serum C-rea

152 es could contribute to complex diseases like Crohn disease and systemic lupus erythematosus, highligh

153 atients (aged >=6 years) with active luminal Crohn's disease at the time of first exposure to inflixi

154 de guidance for medical treatment of luminal Crohn's disease in children.

155 Of the 17 patients with monogenic Crohn's disease, 35% had abdominal pain, 24% had nonbloo

156 an 18 years with quiescent (for 3-24 months) Crohn's disease involving the small bowel with confirmed

157 dysbiosis and pathobiont expansion, notably Crohn's disease (CD).

158 elate their association with the activity of Crohn's disease (CD).

159 We aimed to identify serum biomarkers of Crohn's disease and ulcerative colitis that can be detec

160 ative colitis (UC) and 108 incident cases of Crohn's disease (CD) in patients with microscopic coliti

161 factors have been implicated in the cause of Crohn's disease, including a dysregulated immune system,

162 sense is increased in Treg and Th17-cells of Crohn's disease patients over controls.

163 egy designed to predict the future course of Crohn's disease in patients with quiescent disease.

164 that might contribute to the development of Crohn's disease.

165 discrete-time hazard models for diagnosis of Crohn disease (CD) or ulcerative colitis (UC) among men

166 from patients archived before a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199

167 ylation profiles at the time of diagnosis of Crohn's disease more closely resembled patterns observed

168 on profiles of DNA collected at diagnosis of Crohn's disease vs during the follow-up period showed th

169 of patients who will receive a diagnosis of Crohn's disease within 5 years with high accuracy.

170 d with increased risk of future diagnosis of Crohn's disease.

171 intestinal biopsies that poses diagnosis of Crohn's disease.

172 rography were consistent with a diagnosis of Crohn's disease.

173 h endoscopic findings, led to a diagnosis of Crohn's-like colitis.

174 the MAT contribute to the "creeping fat" of Crohn's disease.

175 A mysterious feature of Crohn's disease (CD) is the extra-intestinal manifestati

176 In ilea of Crohn's disease patients, increased expression of IDO1 c

177 sitic infestations have a lower incidence of Crohn's disease (CD) than nonendemic countries, and ther

178 In the intestine of Crohn's disease patients, CD14(+)CD11(+)CD163(low) macro

179 in intestinal CD14(+)CD11c(+) macrophages of Crohn's disease patients.

180 e effective treatments for the management of Crohn's disease but treatment failure is common.

181 LCV is a rare dermatologic manifestation of Crohn's disease (CD) and may occur with the onset of the

182 splenic nodules as a first manifestation of Crohn's Disease.

183 male SAMP/YitFC mice, a spontaneous model of Crohn's disease-like ileitis.

184 nal CD14(+)CD11c(+) macrophages and mucus of Crohn's disease patients were separated into different c

185 An unusual onset of Crohn's disease with multiple splenic nodules is reporte

186 her IFNL might contribute to pathogenesis of Crohn's disease (CD).

187 n ILCs expressing NKp44 in tonsils and PB of Crohn disease patients, and relatively fewer CD62L(+) IL

188 ly fewer CD62L(+) ILCP were present in PB of Crohn disease patients.

189 icion and capsule severity are predictive of Crohn's disease on initial CE.

190 1 protein biomarkers that were predictive of Crohn's disease within 5 years with an AUROC of 0.76 and

191 The progression of Crohn disease to intestinal stricture formation is poorl

192 be an important factor in the progression of Crohn's disease (CD).

193 In psoriasis patients, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been

194 ent of inflammation and might be a result of Crohn's disease.

195 ion studies as linked with increased risk of Crohn's disease.

196 logy, is upregulated in inflamed segments of Crohn's colon.

197 In re-analysis of a study of Crohn's disease prognosis, four regions remain associate

198 has reached an incidence similar to that of Crohn disease and ulcerative colitis.

199 terocytes from the inflamed ileal tissues of Crohn disease patients compared to uninflamed tissues, r

200 It was approved for the treatment of Crohn disease (CD) on that basis, without specific studi

201 Evidence-based medical treatment of Crohn's disease in children is recommended, with thoroug

202 articipants with irritable bowel syndrome or Crohn's disease were more likely to have continued sympt

203 ment outcomes for ulcerative colitis (UC) or Crohn's disease (CD) patients are limited.

204 disease, multifocal choroiditis, panuveitis, Crohn disease, multiple sclerosis, and relapsing polycho

205 mmatory bowel diseases (IBDs), in particular Crohn's Disease, aseptic splenic abscesses have been rep

206 inflammatory bowel disease(IBD) particularly Crohn's disease(CD), where associations with high and lo

207 Pediatric Crohn's disease is characterized by a higher incidence o

208 we compare scRNA-seq profiles from pediatric Crohn's disease epithelium alongside matched healthy con

209 thin the heterogeneous spectrum of pediatric Crohn's disease (CD) should improve patient management a

210 y studies of medical management of pediatric Crohn's disease.

211 induce remission in patients with pediatric Crohn's disease (CD).

212 vious medical and drug history, and previous Crohn's disease-related surgeries were recorded at basel

213 aseptic abscesses, including IBDs (primarily Crohn's Disease).

214 hronic inflammatory diseases like psoriasis, Crohn's disease (CD), multiple sclerosis (MS), rheumatoi

215 lpha) agents in the management of psoriasis, Crohn's disease, and rheumatoid arthritis.

216 In patients with quiescent Crohn's disease involving the small bowel, faecal calpro

217 le-blind trial of 52 patients with quiescent Crohn's disease or ulcerative colitis and persistent gut

218 arrhea (BAD) is common with ileal resection, Crohn's disease, and diarrhea-predominant irritable bowe

219 an effective therapy for moderate to severe Crohn's disease (CD), its effects on the microscopic man

220 eted a disease activity questionnaire (short Crohn's Disease Activity (sCDAI) or Patient Simple Clini

221 etter overall survival compared to sporadic, Crohn- and hereditary syndrome-related SBA.

222 tion of patients with IBD in the Ocean State Crohn's and Colitis Area Registry (OSCCAR), a community-

223 onic, relapsing condition with two subtypes, Crohn's disease (CD) and ulcerative colitis (UC).

224 GIB) of 46% (246/536) and definite/suspected Crohn's disease (CD) of 39% (210/536).

225 asuring plasma thymidine levels in suspected Crohn's disease to rule out MNGIE, particularly if white

226 y and specificity in patients with suspected Crohn's disease and in the detection of inflammatory act

227 disorders, such as irritable bowel syndrome, Crohn's disease and pancreatitis.

228 These findings indicate that Crohn's disease-associated patterns of DNA methylation o

229 The Crohn's disease risk allele ATG16L1 T300A results in abn

230 imary outcome, defined as an increase in the Crohn's disease activity index score by 70 points or mor

231 the ileostomy patients and in stools of the Crohn's patients.

232 ettings as well as models recapitulating the Crohn disease-associated T300A polymorphism.

233 patients, overlapping substantially with the Crohn disease signature.

234 ells that overlapped to some extent with the Crohn disease signature.

235 Clinical CD activity was measured with the Crohn's Disease Activity Index (CDAI).

236 ctivity on colonoscopy was measured with the Crohn's Disease Endoscopic Index of Severity (CDEIS).

237 d or established CD received the PillCam(TM) Crohn's System as supplementary diagnostic work-up focus

238 ulcerative colitis patients when compared to Crohn's disease patients (27% vs. 5%, P < 0.001) within

239 sociation studies genetically linked IRGM to Crohn's disease and other inflammatory disorders in whic

240 tically susceptible individuals, may lead to Crohn disease.

241 lymphoma, gastrointestinal stromal tumours, Crohn's disease, and groove pancreatitis are discussed.

242 ed in patients with ulcerative colitis (UC), Crohn's disease (CD) and colorectal cancer (CRC).

243 Guts UK, Crohn's and Colitis UK, Cure Crohn's Colitis, AbbVie, Me

244 asmic antibody (ANCA)-associated vasculitis, Crohn's disease, Behcet's disease, eosinophilic granulom

245 istory of CRC, and ulcerative colitis versus Crohn's disease was considered moderate.

246 sy dataset that included healthy volunteers, Crohn's disease and ulcerative colitis patients.

247 of patients with ulcerative colitis (UC) vs Crohn's disease (CD).

248 Twenty-four patients with IBD (11 with Crohn's disease [CD], 13 with ulcerative colitis [UC], m

249 analysis included 329 participants; 168 with Crohn's disease (median sCDAI score 93 [IQR 47-156]), an

250 sy specimens from patients with IBD (30 with Crohn's disease and 27 with ulcerative colitis) and 30 p

251 hildren with a new diagnosis of IBD (71 with Crohn's disease and 41 with ulcerative colitis) and 19 c

252 ty continuous training (MICT)-in adults with Crohn's disease (CD).

253 Most studies evaluated adults with Crohn's disease or ulcerative colitis.

254 osus, and variants have been associated with Crohn disease (CD).

255 on biopsy were significantly associated with Crohn's development (100% vs 11%; P < 0.01) compared wit

256 tis group were significantly associated with Crohn's diagnosis during the follow-up period compared w

257 stinal permeability has been associated with Crohn's disease (CD), but it is not clear whether it is

258 Most CpG methylation changes associated with Crohn's disease disappeared with treatment of inflammati

259 rofiles of CD8(+) T cells from children with Crohn's disease correlated with age but not with disease

260 of the patient's sister, also diagnosed with Crohn's disease, revealed identical variants.

261 olonized with a microbiota from a donor with Crohn's disease.

262 emperate phage sequences in individuals with Crohn's disease.

263 coccus gnavus, a prevalent gut microbe, with Crohn's disease, a major type of inflammatory bowel dise

264 This study included 148 mothers with Crohn disease (CD) and 194 with ulcerative colitis and 6

265 164 pediatric patients (1-17 years old) with Crohn's disease (B1 or B2) who participated in a North A

266 The second patient with Crohn disease underwent emergent laparotomy for a perfor

267 Data were obtained from 409 patients with Crohn disease (CD) who had undergone >=1 ileocolectomies

268 ferentially methylated between patients with Crohn's disease (at diagnosis) and controls.

269 are a frequent complication in patients with Crohn's Disease (CD) and the presence of fibrosis within

270 measure endoscopic activity in patients with Crohn's disease (CD) have limitations.

271 ostoperative disease course of patients with Crohn's disease (CD) who have undergone ileocecal resect

272 ned intestinal tissues from 92 patients with Crohn's disease (CD), 48 patients with ulcerative coliti

273 linical remission in pediatric patients with Crohn's disease (CD).

274 ssment of perianal fistulas in patients with Crohn's disease (CD).

275 ic and histologic remission in patients with Crohn's disease (CD).

276 tests that are used to assess patients with Crohn's Disease (CD).

277 bserved in pediatric and adult patients with Crohn's disease (CD).

278 erianal fistulas are common in patients with Crohn's disease (CD).

279 itor, in a randomized trial of patients with Crohn's disease (CD).

280 ue are commonly reported among patients with Crohn's disease (CD).

281 observed in blood samples from patients with Crohn's disease accompany acute inflammation; with treat

282 A total of 91 patients with Crohn's disease and 102 with ulcerative colitis particip

283 okinetics were measured in six patients with Crohn's disease and evidence of target engagement assess

284 iated with disease activity in patients with Crohn's disease and ulcerative colitis.

285 in blood samples of pediatric patients with Crohn's disease at diagnosis and later time points to id

286 the analyses of microbiomes of patients with Crohn's disease identifies 52 host and 136 microbial pro

287 ed from control individuals vs patients with Crohn's disease or ulcerative colitis did not differ sig

288 Patients with Crohn's disease or ulcerative colitis have relatively hi

289 and colon biopsy samples from patients with Crohn's disease or ulcerative colitis or healthy individ

290 d from healthy individuals and patients with Crohn's disease or ulcerative colitis secreted IL22, whi

291 stations have been reported in patients with Crohn's disease or ulcerative colitis.

292 f these findings, our study of patients with Crohn's disease revealed significantly reduced frequenci

293 cohort of 1240 biologic-naive patients with Crohn's disease starting infliximab or adalimumab therap

294 ere up-regulated in serum from patients with Crohn's disease were identified based on changes in prot

295 non-inferior to infliximab in patients with Crohn's disease who were naive to biological therapy.

296 uced in the small intestine of patients with Crohn's disease, and this correlated with lower frequenc

297 1 and Paneth cell lysozymes in patients with Crohn's disease.

298 evealed an increased amount in patients with Crohn's disease.

299 g colonoscopies (controls) and patients with Crohn's disease.

300 the decreased association of rs10065172 with Crohn's disease in those populations.